Free tool
FAERS Monitor: Zyclara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022483 or its brand name (Zyclara, Imiquimod). Reports on generic versions are filed under their own applications.
Reports
2,334
Serious
1,287
55% of reports
Hospitalization
331
Death reported
73
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use265
- erythema185
- fatigue181
- product use in unapproved indication177
- drug ineffective171
- pain137
- nausea114
- influenza like illness103
- application site erythema102
- headache95
- pruritus88
- pyrexia85
- scab77
- application site pain75
- malaise75
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 9 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 11 |
| 2010 | 15 |
| 2011 | 55 |
| 2012 | 64 |
| 2013 | 69 |
| 2014 | 64 |
| 2015 | 119 |
| 2016 | 198 |
| 2017 | 220 |
| 2018 | 216 |
| 2019 | 185 |
| 2020 | 211 |
| 2021 | 110 |
| 2022 | 166 |
| 2023 | 163 |
| 2024 | 117 |
| 2025 | 180 |
| 2026 | 148 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| scabSignal | 77 | 61.3 | 49.1 | 4,476 |
| application site erythemaSignal | 102 | 35.2 | 29.1 | 3,347 |
| application site painSignal | 75 | 30.8 | 24.6 | 2,127 |
| influenza like illnessSignal | 103 | 11.3 | 9.3 | 958 |
| erythemaSignal | 185 | 8.1 | 7.1 | 1,158 |
| product use in unapproved indicationSignal | 177 | 6.4 | 5.6 | 817 |
| off label useSignal | 265 | 2.7 | 2.4 | 301 |
| pyrexiaSignal | 85 | 2.2 | 1.8 | 56 |
| fatigueSignal | 181 | 2.1 | 1.8 | 106 |
| pruritusSignal | 88 | 2.1 | 1.7 | 48 |
| painSignal | 137 | 2.0 | 1.7 | 71 |
| malaise | 75 | 1.5 | 1.2 | 14 |
| headache | 95 | 1.4 | 1.1 | 9 |
| nausea | 114 | 1.3 | 1.1 | 8 |
| drug ineffective | 171 | 1.2 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.